AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Increase in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 153,264 shares, an increase of 62.0% from the February 26th total of 94,590 shares. Based on an average trading volume of 194,526 shares, the short-interest ratio is currently 0.8 days. Currently, 4.7% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. DRW Securities LLC raised its holdings in AIM ImmunoTech by 60.6% in the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after acquiring an additional 26,254 shares during the period. Sabby Management LLC acquired a new position in shares of AIM ImmunoTech in the third quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech in the second quarter valued at approximately $87,000. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Price Performance

AIM ImmunoTech stock traded up $0.01 during mid-day trading on Friday, hitting $0.70. 304,630 shares of the company’s stock traded hands, compared to its average volume of 9,879,060. The firm has a 50 day simple moving average of $0.98 and a two-hundred day simple moving average of $1.58. AIM ImmunoTech has a fifty-two week low of $0.61 and a fifty-two week high of $36.00. The stock has a market cap of $2.30 million, a price-to-earnings ratio of -0.07 and a beta of 1.26.

Analysts Set New Price Targets

Separately, Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, AIM ImmunoTech has an average rating of “Buy”.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.